Free signup for more
- Track your favorite companies
- Receive email alerts for new filings
- Personalized dashboard of news and more
- Access all data and search results
Filing tables
Filing exhibits
- S-4/A Registration of securities issued in business combination transactions
- 5.1 Opinion of Ellenoff Grossman & Schole LLP
- 8.1 Tax Opinion of Ellenoff Grossman & Schole LLP
- 10.15 Offer Letter, Dated As of July 18, 2016, by and Between Blade Theraueptics, Inc. and Wendye Robbins, M.D
- 10.16 Offer Letter, Dated As of February 1, 2021, by and Between Blade Therapeutics, Inc. and Jean-frederic Viret, PH.D
- 10.17 Offer Letter, Dated As of April 19, 2017, by and Between Blade Therapeutics, Inc. and Prabha Ibrahim, PH.D
- 10.18 Offer Letter, Dated As of September 30, 2016, by and Between Blade Therapeutics, Inc. and Felix Karim, PH.D
- 10.19 Amendment to Offer Letter, Dated As of March 24, 2022, by and Between Blade Biotherapeutics, Inc. and Wendye Robbins, M.D
- 10.20 Amendment to Offer Letter, Dated As of March 24, 2022, by and Between Blade Biotherapeutics, Inc. and Jean-frederic Viret, PH.D
- 10.21 Amendment to Offer Letter, Dated As of March 24, 2022, by and Between Blade Biotherapeutics, Inc. and Prabha Ibrahim, PH.D
- 10.22 Amendment to Offer Letter, Dated As of March 24, 2022, by and Between Blade Biotherapeutics, Inc. and Felix Karim, PH.D
- 23.1 Consent of Marcum LLP
- 23.2 Consent of Ernst and Young LLP, Independent Registered Accounting Firm for Blade Therapeutics, Inc
- 99.2 Consent of Wendye Robbins to Be Named As a Director
- 99.3 Consent of Mark Timney to Be Named As a Director
- 99.4 Consent of Lloyd Klickstein to Be Named As a Director
- 99.5 Consent of James Scopa to Be Named As a Director
- 99.6 Consent of Luke Evnin to Be Named As a Director
- 99.7 Consent of John A. Hohneker, M.D. to Be Named As a Director
- 99.8 Consent of Carl Goldfischer, M.D. to Be Named As a Director
- Download Excel data file
- View Excel data file
Associated filings
- 17 Jun 22 RW Registration withdrawal request
- 23 May 22 424B3 Prospectus supplement
- 10 May 22 EFFECT Notice of effectiveness
- 9 May 22 424B3 Prospectus supplement
- 9 May 22 S-4/A Registration of securities issued in business combination transactions (amended)
- 3 May 22 S-4/A Registration of securities issued in business combination transactions (amended)
-
15 Apr 22 S-4/A Registration of securities issued in business combination transactions (amended)
- 1 Apr 22 S-4/A Registration of securities issued in business combination transactions (amended)
- 15 Mar 22 S-4 Registration of securities issued in business combination transactions
BIOT similar filings
Filing view
External links
Exhibit 99.6
Consent to be Named as a Director
In connection with the filing by Biotech Acquisition Company of the Registration Statement on Form S-4 with the Securities and Exchange Commission under the Securities Act of 1933, as amended (the “Securities Act”), I hereby consent, pursuant to Rule 438 of the Securities Act, to being named in the Registration Statement and any and all amendments and supplements thereto as a member of the board of directors of Biotech Acquisition Company following the consummation of the business combination, which will be renamed Blade Biotherapeutics, Inc. I also consent to the filing of this consent as an exhibit to such Registration Statement and any amendments thereto.
Dated: April 15, 2022
By: | /s/ Luke Evnin | |
Luke Evnin |